Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Geron has announced the publication of data demonstrating the efficacy of its pan-cancer telomerase inhibitor drug GRN163L in mouse models of human hepatocellular carcinoma and human metastatic lung cancer.
Subscribe to our email newsletter
The company says that the liver and lung cancer studies, which are detailed in the journals Hepatology and Cancer Research, respecively, confirm and extend the broad potential of GRN163L for the treatment of cancer, and provide insights into how the drug works in inhibiting tumor growth and tumor metastases.
GRN163L is currently in clinical testing in a phase I/II trial in patients with chronic lymphocytic leukemia, with additional trials being planned.
“These two publications provide detailed analyses in two different model systems of the impact of our pan-cancer drug, GRN163L, on tumor cells in vitro and in vivo, adding to our growing understanding of the potential for GRN163L in the treatment of a broad range of cancers,” stated Dr Calvin Harley, Geron’s chief scientific officer.
“The in vivo studies in each case show that GRN163L inhibited tumor growth at doses which had no apparent toxic effects on the mice. We look forward to results from our current phase I/II human clinical trial in CLL, and future trials in patients with solid tumors,” added Dr Harley.